Lumicell is changing the landscape of cancer surgery with a hand-held imaging system that enables surgeons to identify any cancer cells left behind on the tumor cavity walls and take action in real-time to improve patient outcomes.
Lumicell is addressing the number one challenge in cancer surgery – the need to remove all cancer cells during the first surgery while preserving healthy tissue.
Lumicell Initiates Pivotal Trial for Breast Cancer Surgical Guidance Solution
Lumicell, Inc., an innovation leader in image guided cancer surgery, today announced it has begun its pivotal trial of the Lumicell Imaging System for breast cancer — a major milestone on its path toward FDA submission for approval.
Lumicell Completes Enrollment of Phase C Feasibility Trial for Breast Cancer Surgical Guidance Solution
Lumicell, Inc. an innovation leader in image guided cancer surgery, today announced that it has completed enrollment in its Phase C feasibility clinical trial of the Lumicell Imaging System for breast cancer. With results from the Phase C feasibility trial expected in late 2019, Lumicell expects to begin the pivotal trial by the end of 2019 before applying for FDA approval.
Feasibility Study Underway to Assess Lumicell Technology for Removing Ovarian and Peritoneal Cancer Tumors During the First Surgery
Lumicell, Inc. today announced that a feasibility study is underway at Massachusetts General Hospital in Boston to determine the initial safety and efficacy of its Lumicell System for in vivo imaging of metastases to the peritoneum from primary ovarian cancer, appendiceal cancer, gastrointestinal cancer and mesothelioma.
Lumicell Headquarters Expands Into New Boston-Area Office Space
Lumicell, Inc., an innovation leader in molecular imaging within healthcare focused in cancer, perfusion, wound care and infection, has expanded into a new headquarters location in Newton, Mass., just outside of Boston.
Lumicell Selected to Present at the Food & Drug Administration's Optical Imaging Workshop
Lumicell's SVP of Product Development, Jorge Ferrer Ph.D., is presenting at the workshop, "Translational Pathways for Optical Drugs and Devices for Cancer Imaging" hosted by the Food and Drug Administration in collaboration with The National Cancer Institute and the University of Maryland Centers of Excellence in Regulatory Science and Innovation.
Kevin Hershberger Joins Lumicell as Chief Financial Officer
Hershberger brings over 25 years of global financial management experience from a variety of life science products and manufacturing companies
Lumicell Expands Board with Addition of Michael Ruettgers
Industry executive with history of building successful Boston-based businesses will serve as an advisor to the development of Lumicell’s growth and long-term business strategies
Lumicell Launches Wound Care Infection and Perfusion Division
New business unit aims to tackle challenges around chronic wounds
Lumicell Forms Scientific Advisory Board To Drive Future Innovations
Members will serve as key advisors and foundational partners in the development of Lumicell technology
CEO Today officially announced the full list of finalists and, of course, the winners of their 2018 Business Women of the Year Awards. Proud to have Lumicell's own CEO, Kelly Londy, featured!
Lumicell Reports Positive Clinical Results with LUM System Demonstrating Rapid Identification of Residual Tumor in Lumpectomy Cavity of Patients with Breast Cancer
Data Published by Investigators at Massachusetts General Hospital in the Journal of Breast Cancer Research and Treatment
Catching Every Cancer Cell While in Surgery
A veterinary surgeon at Tufts tests and experimental imaging technology on dogs being treated for cancer
This New Technology Could Help Surgeons Clear Out Leftover Cancer Cells
In some instances, as many as 30% of patients need repeat surgeries to get rid of cancerous cells initially left behind. The team from Lumicell wants to change that — and improve outcomes for cancer patients.